Skip to content

Debatforum

20.6k Emner 126.8k Indlæg

Aktie- og finansdebat

  • Trevor Milton forlader Nikola!

    6
    0 Votes
    6 Indlæg
    0 Visninger
    M
    Breaking news! Så er Nikolas formand Trevor Milton gået af. Så er der lige en hurtig video klar med min vurdering af sagen med Trevor Milton. Som skrevet tidligere, så er han gået af som formand for Nikola, hvilket var helt som ventet . Spørgsmålet er nu, hvordan investorerne tolker dette. Er det et bevis på Nikolas undergang eller er det en lettelse, så Nikola nu kan komme videre. Det bliver spændende at se . Det bliver også interessant for de virksomheder, der er steget meget i kølvandet på Nikola-hypen. Og her er norske NEL en af dem, man skal holde øje med. https://www.youtube.com/watch?v=IN52Losc1KA&fbclid=IwAR10frGxAjD6rm1GOGmth5_ck7p-4KZohF3cfgrR-KdGe-FiEJTH2VafmIs
  • Chargepoint - En spændende mulighed i en spekulativ sektor

    0
    0 Votes
    0 Indlæg
    0 Visninger
    M
    Godaften til jer alle, Så er dagens video klar. Som skrevet tidligere, så er videoen her om virksomheden Chargepoint, som jeg er temmelig begejstret for. På EV-fronten vil der i de kommende år blive massivt brug for lademuligheder, og her kommer Chargepoint ind i billedet. Det negative er, at de stadig giver minus på bundlinjen, og også kommer til at gøre det i de næste 3-5 år. Men udviklingspotentialet er massivt, og hvis du vil ind i en spekulativ aktie med store muligheder (og risici selvfølgelig), så bør du tage et nærmere kig på Chargepoint. https://www.youtube.com/watch?v=fy_WrOR-0ks&fbclid=IwAR07Ol7xjthNS1Ucr0j2F4uz6DyJskSKS222vbfwEmq5Jxn941ybpWYgW5Q
  • Hvad er en SPAC ?

    0
    0 Votes
    0 Indlæg
    0 Visninger
    W
    God forklaring af Patrick Boyle https://www.youtube.com/watch?v=GrWgFNmvEwE
  • De "store drenge" køber ind i Cantargia

    0
    0 Votes
    0 Indlæg
    0 Visninger
    A
    De må have fået øje på potentialet i Cantargia .....imponerende stigning idag... Største købere Morgan Stanley Europe SE 112135 55321 56814 3270 Carnegie Investment Bank AB 30209 2000 28209 0 Goldman Sachs International 34178 11173 23005 199 UBS Limited 14020 1457 12563 0 Instinet Europe Ltd. 12788 500 12288
  • 2cureX - Last patient successfully enrolled

    5
    0 Votes
    5 Indlæg
    0 Visninger
    Helge_LarsenPI-redaktørH
    Last patient successfully enrolled in the world's first interventional trial with 3D microtumors as guide for choice of cancer treatment. 2020-10-01 Press Releases Regulatory According to schedule, 2cureX's clinical partner University Hospital Vejle today enrolled the last patient in the clinical validation study TICC1. In this interventional study, IndiTreat test results guide the drug treatment of patients with metastatic colorectal cancer who have exhausted guideline-based treatment options. The TICC1 clinical trial (Clinicaltrials.gov no. NCT03251612) was launched end 2017 with the purpose of evaluating IndiTreat's ability to successfully guide the drug therapy of end-stage metastatic colorectal cancer patients. As planned in the trial protocol, 45 patients have been enrolled and treated in accordance with the IndiTreat results. This trial is the world's first interventional trial where patient treatment is guided by 3D microtumor technology. Appealing method for both oncologists and patients "The concept of testing the effects of drugs directly on the patient's tumor cells in the laboratory is very appealing to both oncologists and our patients. Back in 2017 we suggested using the IndiTreat test to screen a panel of standard and off-label drugs to identify treatments to which the patient was sensitive and exclude drugs the patient was resistant to. It is a great pleasure that we have now completed the inclusion of patients for this trial. The last patient will now be treated according to the test result, and the outcome will be evaluated after eight weeks. The results of the study will be published when all data have been analyzed", says Lars Henrik Jensen, Principal Investigator at University Hospital Vejle. Inditreat will empower oncologist to choose the best possible treatment "At the moment, there is no evidence-based treatment recommendation for patients when guideline recommendations are exhausted. The ambition of the novel IndiTreat test is to empower oncologists to choose the best possible treatment even for severely sick patients such as those included in the TICC1 trial. We therefore eagerly await the results of this pivotal trial", says Henrik Harling, Chief Medical Officer at 2cureX. Important milestone We have now met a very important milestone, and I want to thank University Hospital Vejle for their forward looking and highly professional management of this trial carried out according to schedule. I believe this study will demonstrate that IndiTreat is able to predict which drugs should be used for the individual patient suffering from colorectal cancer. We started with patients suffering from the most advanced form of colorectal cancer. If our expectations are met, it may result in a paradigm shift in cancer drug treatment", says Ole Thastrup, CEO of 2cureX. For more information about 2cureX, please contact: Ole Thastrup, CEO E-post: [email protected] Telefon: +45 22 11 53 99 www.2curex.com Certified Adviser Redeye AB Telefon: +46 8 121 576 90 E-mail: [email protected] This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on October 1st, 2020. About 2cureX 2cureX has developed the IndiTreat (Individual Treatment) test. IndiTreat establishes thousands of 3D micro-tumors that are similar to the patient's tumor and identifies the treatment that most effectively kills the patient's tumor and the treatment to which the patient is resistant. Immediately after the test, the patient can be offered the selected treatment. IndiTreat is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany, Sweden and United Kingdom. IndiTreat is presently being introduced into the European market. The aspiration is that IndiTreat becomes a standard Functional Precision Medicine tool for cancer patients. The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). https://www.2curex.com/last-patient-successfully-enrolled-in-the-worlds-first-interventional-trial-with-3d-microtumors-as-guide-for-choice-of-cancer-treatment/
  • Lån til investering

    15
    0 Votes
    15 Indlæg
    0 Visninger
    F
    Jeg har prøvet at kigge lidt rundt hos Nordnet og Saxo om mulighederne for at låne til investering. Jeg ved godt rigtig mange vil sige "lån ikke penge" eller "invester ikke mere end du kan tåle at tabe". Men hvis muligt, er jeg på udkig efter lån fra 1mio og opefter til renter på ikke mere end 2%. Investere dem i passive indeksfonde og lade dem stå 10-15år. Sikkerheden i lånet skulle være i selve porteføljen. Er der andre der har gjort dette? Og hvis ja - hvor?
  • Teknisk analyse af Bakkafrost

    2
    0 Votes
    2 Indlæg
    0 Visninger
    Helge_LarsenPI-redaktørH
    Trend: Kort sigt - Sidelæns interval Lang sigt - Op Aktuel pris: 570 NOK Kort sigt: Aktien har på kortsigt bevæget sig i et sidelæns interval siden februar 2020 og frem til i dag. Her har aktien bevæget sig med top og modstandsniveau i kurs 720 NOK og med bund og støtteniveau i kurs 452 NOK. I dag kan aktien handles til 570 NOK. Lang sigt: På lang sigt har aktien været i en optrend. Denne optrend begyndte helt tilbage i november 2011, hvor aktien lå nede ved bund og støtteniveau i kurs 30 NOK. Herfra og frem til februar 2020 steg aktien til kurs 720 NOK, der ligeledes er den foreløbige all time high. Her har aktien stort set kun steget med højere toppe og bunde, og brudt den ene all time high efter den anden. Siden da korrigerede aktien på en måned kraftigt nedad til kurs 452 NOK, og har siden bevæget sig indenfor det føromtalte sidelænsinterval med top og modstandsniveau i kurs 720 kroner og med bund og støtteniveau i kurs 452 NOK. Opadgående retning: På kort sigt bevæger aktien sig i et sidelænsinterval, med første top og modstandsniveau i kurs 632 NOK. Bliver dette niveau brudt nedefra og op, vil aktien forsøge at søge videre op mod næste top og modstandsniveau i kurs 720 NOK. Bryder aktien ligeledes dette nivau nedefra og op, vil aktien have brudt ud af sit sidelænsinterval og dermed bekræfte at trenden igen er optrend både på kort og lang sigt. Samtidig vil aktien have fuldendt sin bundformation med toppe i kurs 720 NOK og bund i kurs 452 NOK. Med denne bundformation vil man teknisk set indikeres et target i kurs 985 NOK, der også vil være ny all time high. Nedadgående retning: Her er der støtte til aktien første gang ved bund i kurs 532 NOK. Dernæst i bund i kurs 490 NOK og herefter støtte i sidelænsintervallets bund i kurs 452 NOK. Brud herunder oppefra og ned vil bekræfte, at aktien har brudt ud af sit sidelænsinterval og er dermed i nedtrend. Her vil aktien potentielt forsøge at søge støtte nede ved bund i kurs 251 NOK fra april 2017. Afgørende bunde og støtteniveauer: 532 NOK, 490 NOK, 452 NOK og 251 NOK . Afgørende toppe og modstandsniveauer: 632 NOK og 720 NOK. De tekniske indikatorer bevæger sig i sidelæns interval på bådedag og ugegrafen. Til gengæld ser de tekniske indikatorer på månedsgrafen mere positive ud, hvilket kan indikere at trenden på lang sigt skal opad. Af Rida Abu-Shumar/ProInvestors Analyseteam [image: 86928_Chart___Bakkafrost_d._21.09.20_.png]
  • Orphazyme analyse fra Red Eye

    9
    0 Votes
    9 Indlæg
    0 Visninger
    A
    https://www.redeye.se/research/794077/orphazyme-our-view-on-the-latest-news?utm_source=MB&utm_medium=email
  • Afsnit 33 af Investeringspodcasten Hansen&Larsen

    0
    0 Votes
    0 Indlæg
    0 Visninger
    Helge_LarsenPI-redaktørH
    I afsnit 33 af #Investeringspodcasten tager Hansen og Larsen fat på tirsdagens valgdebat mellem Trump og Biden og betydningen af det kommende amerikanske valg. Herudover diskuterer de to garvede investorer, hvorvidt udbytte eller aktietilbagekøb er bedst - eller måske en kombination som det ses hos nogle selskaber? Og er det noget, der kan påvirke aktiekursen i den ene eller anden retning? Også ejerstrukturen, prisfastsættelsen og den aktuelle ledelse kan være faktorer, der er afgørende for, om et aktieselskab skal udbetale udbytte eller købe aktier tilbage. Er der forskel på et kursmål, der er drevet af værdiansættelsen eller et indtjeningsmæssigt momentum? Det korte svar er ja. Et kursmål er ikke bare et kursmål. Hvornår er det bedste tidspunkt at købe og sælge aktier? Kan man benytte forskellige teknikker til ikke at ramme helt forkert? Og skal man være bange for, at en stigende aktie er ved at toppe? Og hvordan forholder det sig nu med investeringer på hjemmemarkedet vs. investeringer globalt set? Hansen og Larsen tager temperaturen på danskernes placering af aktier udenfor landets grænser. 00:41 - 04:50 Trump vs. Biden 05:05 - 14:35 Udbytte vs. aktietilbagekøb 14:35 - 18:50 Kursmål og tilbageblik på afsnit 23 18:50 - 22:06 Hvornår er det bedst at købe og sælge aktier? 22:06 - 27:38 Home bias eller globalt udsyn? Se med på vores YouTube eller find podcasten på Spotify,iTunes- eller der hvor du lytter til podcasts. https://www.youtube.com/watch?v=00p-bKaHdQ4
  • Tid til flere kontanter ?

    32
    0 Votes
    32 Indlæg
    0 Visninger
    D
    Jeg er sikkert ikke ene om at være noget overrumplet over, at værdien af porteføljen ligger højere nu end ultimo februar før Coronakrisen satte ind. Helt konkret er jeg oppe med ca 20 pct år/dato og det er jo ikke enestående, da det for det meste har været drevet af udviklingen i det generelle marked, og så den lille krølle, at min kontantbeholdning blev sat i arbejde i løbet at marts måned, da krisen rasede. Men mine fundamentale instinkter har det meget svært i øjeblikket, da aktiemarkederne opfører sig helt surrealistisk, for det kan da ikke fortsætte vel ? Toppen af nerverne er taget ved at sælge lidt ud her i de sidste dage, så kontantbeholdningen er på knap 20 pct., og så bliver der jo også lidt til skattefar, for velfærdsstaten finansierer jo ikke sig selv. Men noget i mig presser på for at sælge mere ud, men jeg prøver at holde fingrene fra salgsknappen. Hvilke overvejelser gør i andre jer, er det sælg eller hold ?
  • Hvordan tjener man penge på sektorrotation?

    0
    0 Votes
    0 Indlæg
    0 Visninger
    M
    Jeg bliver ofte spurgt til begrebet "sektorrotation", så jeg tænkte, at det ville være på sin plads med en lille video om emnet. Især fordi, vi muligvis er i fuld gang med en sådan rotation mellem flere sektorer. I videoen viser jeg både, hvordan jeg finder de gode sektorer, samt gennemgår et par aktier, der kunne være interessante, hvis teorien om rotationen er korrekt. https://www.youtube.com/watch?v=gu-46zcBwsI&fbclid=IwAR17S1GvGQ83CudEpbhryrqv3s74QTgbC_RFVgw5HFEQeCw6bssK5iweijk
  • Morningstar om Palantir

    0
    0 Votes
    0 Indlæg
    0 Visninger
    tommycarstensenT
    Hvis jeg skulle vælge mellem at alliere mig med Peter Thiel eller Saruman, så tror jeg, at jeg ville vælge sidstnævnte Interessant skriv fra Morningstar om Palantir nedenfor. Peering Into Palantir's Data Market Disruption https://www.morningstar.com/articles/1002517/article We value the company at $28.2 billion, reinforced by a sticky customer base and positive moat trend. Mark Cash Sep 25, 2020 SEC filings and investor presentations have pulled back the curtain on Palantir Technologies' (PLTR) opaque operations, and we are intrigued by the company's prospects as an emerging leader in data integration, analytics, and artificial intelligence. We anticipate the company will come public on Sept. 30 via a direct listing; we value it at about $28.2 billion in equity value, or about $13 per share based on an estimate of 2.17 billion shares. We believe Palantir has a narrow economic moat and a positive moat trend based on customer switching costs, intangible assets, and a network effect. In our view, Palantir's government and enterprise software has become mission-critical and deeply engrained with clients, the company has unique customer and market knowledge to pair with its AI acumen, and its software platforms become stronger as more users, institutions, and industries rely on its solutions. We believe these sources will strengthen, and despite a lack of profitability today, we anticipate that Palantir will generate robust operating leverage and excess returns in the long run. Our estimated 34% five-year revenue compound annual growth rate is driven by robust growth in government and commercial sectors. Providing a holistic view of legacy data from disparate locations and various types, integrating the influx of new data, and then using AI to extract actionable insights can give organizations an advantage over peers. However, firms and governments attacking the challenge in-house can be unsurmountable. From assisting top-secret intelligence operations to extracting the optimal amount of oil out of wells to predictive maintenance on airplanes, Palantir is a disruptive force by selling commercial software platforms versus highly customized, consulting-led efforts. We view Palantir as a land-and-expand story: After converting trial customers to its software platform, its software subscriptions proliferate in organizations and the incremental revenue outpaces associated investments required. With improvements in up-front installation costs and the cadence of subsequent software updates, we expect substantial operating margin improvement to the mid- to high 20s on an adjusted basis by 2025, up from negative 45% in 2019. Palantir Aims to Solve Customers' Problems With Big Data Palantir's products are aimed at first enabling institutions to integrate all their legacy and constant influx of new data, regardless of format, device, or location. The software provides a holistic view of data for testing, insight, pattern analysis, and what-if scenarios and allows technical and nontechnical users to all collaborate within the same platform. Next, its data operating system provides customers with the ability to extract insights from seemingly disparate data patterns or connections with AI. Palantir's software platforms can be deployed in any environment and buck the trend of requiring highly customized solutions. In addition to the functionality its software platforms are providing, Palantir aims to solve the historically terrible rate of success in data integration and insight-producing projects, while also not requiring customers to displace legacy investments. Its software platforms enable self-sufficient customers whereby Palantir is providing software updates, but insights can be gleaned internally. The company sells two software platforms: Gotham, mostly targeted at government operations, and Foundry, aimed at commercial markets. Launched in 2008, Gotham's provenance was assisting U.S. counterterrorism operations to find insight from their data, and alleviating the data organizational issues and dangers of soldiers in Afghanistan and Iraq mapping insurgent networks and roadside bomb makers manually. Over time, Palantir expanded into the commercial segment. While the stakes may be different, the challenges of integrating new and legacy data sets and gleaning insight from copious amounts of data are ubiquitous. Foundry was developed to make the integration of data sets routine in addition to gaining insights through AI. These platforms are sold across their customer segments as well, with financial institutions using Gotham for fraud investigation and Foundry being used across government divisions. Under the hood, Palantir's Apollo platform is software that controls and updates its offerings, also enabling Gotham and Foundry to be deployed in clouds, on-premises, classified networks, edge networks, and devices. Palantir credits innovation in the Apollo platform as its way to achieve margins resembling those of software as a service instead of operating like a consulting business, all hidden to the end users of Gotham and Foundry. Strategy Has Evolved Starting as a company specializing in government intelligence software in 2003, Palantir's business model more likely resembled a consulting firm employed for defense contracting work. This model can require a lot of manual labor, working to build customized solutions to solve a specific problem at a point in time. Issues arise when attempting to scale that particular solution to other related challenges, whether across particular institutions or market segments. With its foray into the commercial markets, Palantir was also initially operating a consulting model upon releasing Foundry in 2016. The following year, the company migrated commercial customers to a software platform instead of bespoke applications. While the firm may have lost customers during this process, we believe having a commercialized platform is the correct strategic play in the long run. Palantir has evolved toward a SaaS company, with all its customers using its software platforms. Palantir's development team rotates into the field to understand customer- and industry-specific challenges firsthand, and then updates its platforms to meet the tasks. The company retains the intellectual property gained through these improvements. It typically provides its solutions at no cost for a trial period. Importantly, Palantir is coming to companies with a solution from the get-go, instead of a plan of integrating data before tackling the analytics implementation. These loss-leading efforts turn into customers as Palantir supports prospects with engineers for installation and software training. Palantir's engineers return from the field as customers become self-sufficient with the software. Palantir's revenue streams are more globally and sector diversified than most investors may suspect, in our view. The company sells its platforms to the United States and allies on the government side and into a variety of commercial industries, in total 36 industries across 150 countries. While we expect U.S. government customers to remain a cornerstone of Palantir's business, 53% of revenue was commercial-based and 60% of revenue was derived outside the U.S. at the end of 2019. The impact of these strategic changes is accelerating revenue streams alongside an improved operating profile. Margin expansion comes from lower deployment costs, proliferation of its platforms throughout existing client organizations, and properly pricing its software platform to maximize the value that customers receive. Moat Is Underpinned by High Customer Switching Costs We assign Palantir a narrow economic moat rating, primarily based on customer switching costs and secondarily strengthened with a network effect and intangible assets. Despite a lack of profitability today, we anticipate that Palantir will rely on these moat sources to generate robust operating leverage and excess returns in the long run. Data proliferation is only accelerating as organizations further interconnect disparate systems across on-premises, private clouds, public clouds, edge locations, and personnel and devices. We believe the explosion of data and the management of data in a variety of formats presents a confounding issue for organizations. Palantir sells software solutions aimed at solving the issues of data integration without requiring organizations to start from scratch and provides a centralized view to gain insight from the data through AI supporting manual operations. We believe that Palantir's software platforms have become mission-critical for governments and enterprises and cultivate high customer switching costs. The company targets large-scale data operations in global enterprises and governments and further focuses on complex situations that have high installation costs and elevated stakes upon failure. Implementation and integration of software and associated data can create large barriers to changing from software that is providing a crucial function for business operations. As particular software platforms become more widely spread within organizations, the higher the cost of changing vendors, in our view. Palantir's sales motion is predicated on acquiring, expanding, and scaling accounts. The acquire phase typically provides customers with short-term pilot deployments of Palantir's software at little to no cost for the customer. Palantir ramps up its investment in the expand stage to understand the particular issues faced by the customer and its industry. This strategy aims to ensure that the software provides appreciable value in an attempt to lock the customer into the ecosystem. Scaling is when revenue outpaces incremental investments, margins improve, and Palantir's platform starts to proliferate within organizations. Palantir has historically operated at a loss, which we expect to continue on a GAAP basis until later in the 2020-29 decade as it ramps up sales, marketing, and infrastructure investments to seize its market opportunity. Nonetheless, we believe that profound improvements in margins through decreasing the time and number of engineers required to install, deploy, and manage the software platforms, alongside scaling the customer cohort, will lead to sustainable excess returns on invested capital in the long run. In our view, Palantir is a beneficiary of high customer switching costs. It does not require organizations to completely overhaul their existing technology and infrastructure investments. Its software platforms integrate with customers' historical systems, and new data sources and methodologies can be added to the data operating system. We think this integration will make it especially difficult for customers to quickly switch to alternate vendors, and we believe that this gives Palantir flexibility to address many use cases while becoming critical to operations. Palantir Also Benefits From Network Effects and Intangible Assets Palantir's platforms are intended to be collaborative across entire organizations: Developers and data scientists can write custom applications on top of the platforms in their chosen coding language while nontechnical individuals can use the platforms and make actionable decisions. By transforming data into common vernacular and views that are easily comprehensible, we believe a network effect exists within organizations as well. Each additional user brings a unique viewpoint and the platforms can spread across an institution. With data constantly being ingested and analyzed, Palantir's platforms can uncover new insight and notify appropriate individuals that may have not been privy to the new information, making the platforms more powerful as more users participate. Going further, Palantir has been able to establish its platforms as the data operating system within government operations and the airline industry, with partnership plans intended for the healthcare and financial services industries as well. We also believe that Palantir has valuable intangible assets associated with specific customer and industry acumen. In an approach to alleviate the issues with these complex projects that can rely on a patchwork of solutions, Palantir rotates its software engineers between field and development efforts to gain insight about customer and industry-specific challenges that can strengthen its platforms' capabilities. We believe that this unique customer and industry acumen creates intangible assets for Palantir's platforms, while also fortifying a network effect. As of December 2019, Palantir had 475 U.S. patents and over 500 patents outside the U.S., as well as 800 patents pending in total. Its software is built with stringent security, auditing, and compliance capabilities while still enabling functionality and collaboration. Moat Trend Is Positive We believe that Palantir's narrow moat is strengthening. Most important, in our view, customer switching costs are increasing as the company's platforms experience strong business expansion within customer cohorts. We also think the network effect is strengthening from expanding use cases across a wider gamut of market verticals and deeper penetration within existing customers. Similarly, intangible assets are increasing as more industry-specific acumen is learned and deployed within its software platform. Supporting these traits are a critical legal ruling in favor of the company and streamlined operations simplifying and hastening software deployment while positively effecting margins. Additionally, the secular trend of massive data proliferation and interconnectivity should drive increased demand for seeking insights from data generated and stored, in our view. We believe Big Data analytics and successfully using AI to uncover insights are in the early stages of adoption, and being able to provide standardized commercial solutions could be the disruptive force across customer markets. As Palantir continues its expansion and customer acceptance into various industry verticals, we believe the company gains unique industry knowledge that strengthens its products and creates a more robust ecosystem of customers utilizing its data operating systems. The company's customer switching costs increase as its software platforms propagate throughout various teams and divisions within organizations after initial acceptance within a subsegment. While we expect Palantir's government vertical to remain critical to growth, the expansion into commercial verticals helps diversify its revenue stream and increases the chances of becoming the de facto data operating system for industries. Our Fair Value Estimate is $13 per Share We value Palantir at $13 per share, which approximates to a $28.2 billion market capitalization based on an estimate of 2.17 billion shares. Our fair value estimate is consistent with a 2020 enterprise value/sales multiple of 23 times and free cash flow yield of 1%. While we recognize these multiples are high, we also foresee rapidly growing and operating leverage for Palantir in the years ahead. We forecast a 34% five-year revenue CAGR driven by Palantir expanding its government and commercial operations. By segment, we model the government sector growing quicker in the near term, with a 37% five-year revenue CAGR, while the commercial segment has a 31% five-year revenue CAGR. Looking further out, we expect the revenue contribution from the commercial segment to surpass the government sector late in the 2020-29 decade. In the government sector, we believe Palantir's successful lawsuit regarding U.S. government agencies considering commercially available options before custom alternatives should propel robust growth, and having incumbency should help the company become the data operating system standard. Our forecast for revenue growth from the government is not materially contingent on the outcome of the 2020 U.S. presidential election or any other geopolitical risks in the years ahead, such as further U.S.-China trade tensions or military conflicts with other regions. For the commercial segment, we expect strong growth as more companies and industries strive to understand actionable insights from their data stores and new data generated. We believe the company has opportunities, as it has done within aviation, to become the de facto data operating system that various clients feed data streams into within the commercial sector. Led by the company requiring fewer resources to deploy its platforms, higher-margin commercial contracts, expansion of government deals, and economies of scale for hosting its software, we model gross margins expanding into the low 80s through the 2020s versus 67% in 2019. We believe that after it wins accounts, Palantir can proliferate its software through organizations as firms look to extract insights by further stitching disparate data sources together. With higher gross margins and less incremental investment required for sales and development per customer, we expect operating margin expansion per customer over time. We model the GAAP operating margin expanding to the low double digits in 2025, from negative 78% in 2019, and the adjusted operating margin expanding into the mid- to high 20s in 2025, compared with negative 45% in 2019. Financially Strong and Improving We believe that Palantir is in a solid financial position that is on a positive trajectory. The company has historically operated at a loss while producing negative operating cash flow; however, we expect these results to improve throughout the 2020s. We believe rapid revenue growth alongside an improving margin profile will help generate bottom-line improvements alongside positive free cash flow. The company's existing customer base generates the bulk of revenue, which we believe gives high visibility and an opportunity to expand customer margins. Although we suspect that Palantir can generate positive free cash flow and become profitable on an adjusted basis in the next few years after adding back copious amounts of stock-based compensation, we believe that GAAP profitability may not come until the middle to latter half of the 2020s. We expect expansion into the commercial market, proliferation across government sectors, and decreasing the expenses required to initially deploy its software platforms will drive Palantir's operating profile and cash flow improvements. As of the end of June, Palantir had an accumulated deficit of $4 billion, $300 million of outstanding debt due in 2023, and $1.5 billion of cash and cash equivalents, excluding restricted cash. The company chose to use a direct listing to join the public markets, so no cash will be raised during the initial public offering. According to PitchBook data, Palantir's Series K funding round in 2016 provided a post-money valuation of around $20.3 billion. The company received subsequent funding from private sources and strategic partnerships, but using its S-1 volume-weighted stock price for August 2020 and the pro forma share count after going public implies its market capitalization may have dropped substantially. However, we believe that strategic initiatives to expand its enterprise software subscription business, alongside sticky government deals, could reward investors over the long run. Some Notable Risks We assign Palantir a high fair value uncertainty rating. The integration of disparate data sources and uncovering actionable insights with the assistance of AI is challenging and may not be a widespread problem that customers require to be solved. While Palantir may be able to execute on this task, a big enough market may not exist, pushing the company into a niche. Palantir's top 20 customers represented 67% of revenue in 2019. As of its IPO filing, Palantir had a small customer base of 125 institutions, so losing any key government or commercial customers, which have flexibility not to expand contracts with the firm, could be overly damaging. Palantir has also stated its intention to not enter contracts with organizations that it considers inconsistent with its mission to support Western liberal democracy and its strategic allies, including the Chinese market. This limits overall market size and could increase cyberattacks, and working with military operations could cause potential investors to avoid the name. A differentiated selling point is the commercial aspect of Palantir's software platforms; however, customers may choose to keep their historical method of employing consultants and system integrators to assist in-house developments for data projects. Alternatively, large established firms may attempt to copy its commercial approach and limit any premium Palantir can demand. Without strong revenue growth and an improving operating profile, Palantir may not achieve profitability. The company went through many rounds of funding before announcing its direct listing, and investors may not be willing to support a long-term, arduous journey to profitability and possible shareholder returns. Palantir has three share classes. Class A has one vote per share and Class B has 10 votes per share and is convertible to one share of Class A. Class F has a variable number of votes and provides the founders with the ability to control nearly 50% of total voting power. As long as 20 million shares of convertible stock remain outstanding from Palantir's Series C, D, and E rounds, the holders of these shares, voting as a single entity, can elect one board member out of the six (at the time of the S-1 filing). Holders of Class A and B shares, voting as a single entity, elect two board members. The combined holders of outstanding convertible preferred stock and common stock elect the remaining board members. With this structure, we believe that Class A investors have to be comfortable with trusting the founders' strategic imperatives and use of capital. Investors also must be comfortable with Palantir's beliefs and ideals. The company will forgo opportunities, however lucrative, if it believes they do not match its culture, knowing that these contracts will go to competitors. With the voting power concentration, we believe investors must be comfortable with Palantir not taking part in deals that are not aligned with its vision to support Western liberal democracy and its strategic allies. In our view, Palantir is making the best long-term strategic decision for its business, and not wavering from that stance could be fruitful in winning future government deals with the U.S. and its allies. We also believe the expansion into commercial markets and previous investments to improve installation costs are moves in the correct direction for the entire business. The company has been criticized in the U.S. for how its software may be used to infringe upon civil liberties and data privacy concerns. Palantir believes it has purposely developed its software to safeguard such concerns; it also employs a privacy and civil liberties team to help customers use its technology responsibly. Palantir does not mine, purchase, or monetize data, and the data is owned by its customers. We do not expect any shareholder returns through common dividends. Share repurchases may occur as the company's presence in the public market matures, but we believe investments in development and sales would be the best use of capital during the rapid-growth stage. [image: 87177_images__18_.jpeg]
  • Bloom Energy - et (næsten) brint-selskab

    0
    0 Votes
    0 Indlæg
    0 Visninger
    M
    Her får I seneste video i serien om Brint-virksomheder. I dag kigges der på Bloom Energy, der ofte nævnes i denne sammenhæng. Bloom Energy leverer løsning til produktion af el via naturgas, biogas eller brint som en del af nødforsyninger ved svigt i elnettet. De står dog overfor en række udfordringer, idet der er heftig konkurrence fra batterier som opladningsenheder. Derudover har Bloom Energy påstået, at de er væsentligt billigere end almindelig el fra el-nettet. Denne påstand dykker jeg lidt ned i, da det muligvis ikke er helt korrekt. https://www.youtube.com/watch?v=Y5ypJJPn5eE
  • Teknisk analyse af Hansa Biopharma

    0
    0 Votes
    0 Indlæg
    0 Visninger
    Helge_LarsenPI-redaktørH
    Trend: Kort sigt - Optrend Lang sigt - Sidelæns interval Aktuel pris: 240 SEK Kort sigt: Aktien har på kort sigt bevæget sig i optrend siden marts 2020 og frem til i dag. Her har aktien bevæget sig med bund og støtteniveau i kurs 59 SEK og med top og modstandsniveau i kurs 288 SEK. I dag kan aktien handles til kurs 240 SEK. Lang sigt: På lang sigt har aktien bevæget sig i et sidelænsinterval. Dette sidelænsinterval begyndte i oktober 2018 og er fortsat aktivt i dag. Her har aktien bevæget sig med top og modstandsniveau i kurs 349 SEK der også er all time high og med bund og støtteniveau i kurs 59 SEK. Opadgående retning: I opadgående retning har aktien første top og modstandsniveau i kurs 288 SEK. Bliver dette niveau brudt nedefra og op vil aktien forsøge at komme videre op mod næste top i kurs 349 SEK. Bryder aktien denne kurs vil aktien fuldende en bundformation,og dermed frembringe et stærkt køb signal. Bundformationen har bund og støtteniveau i kurs 59 SEK og top og modstandsniveau i kurs 349 SEK.D enne bundformation kan indikere et target oppe i kurs 650 SEK. Nedadgående retning: Her er der støtte til aktien ved bund i kurs 186 SEK. Dernæst ved bund i kurs 117 SEK og dernæst ved bund i kurs 59 SEK. Bryder aktien dette støtte og modstandsniveau, vil trenden være vendt til ned. Afgørende bunde og støtteniveauer: 186k SEK, 117 SEK og 59 SEK. Afgørende toppe og modstandsniveauer: 288 SEK og 349 SEK. De tekniske indikatorer bevæger sig i sidelæns retning på daggrafen. Til gengæld ser de tekniske indikatorer mere positive ud på både uge og månedsgrafen, hvilket kan indikere, at aktien på lang sigt vil forsøge at søge opad. Rida Abu-Shumar/Proinvestors Analyseteam [image: 87172_Chart___Hansa_Biopharma_d._29.09.20_.png]
  • Nordnet kursfest

    1
    0 Votes
    1 Indlæg
    0 Visninger
    S
    På min skærm ser det ud til at nordnet har sammenlagt dagens med gårdsdagens stignings/fald procenter, f.eks SAS plus 56 %. Er det samme hos jer? f.eks link: https://www.nordnet.dk/markedet/aktiekurser?selectedTab=prices&sortField=name&sortOrder=asc&exchangeCountry=DK&exchangeList=dk%3Alargecapcopenhagendkk&exchangeList=dk%3Amidcapcopenhagendkk
  • Bioporto vil sælge nye aktier - hvorfor stiger aktien?

    16
    0 Votes
    16 Indlæg
    0 Visninger
    H
    Bioporto vil sælge nye aktier for over 100 millioner. Kursen stiger efter at nyheden kom frem i dag, og det forstår jeg ikke. Som jeg har oplevet det i de 8 måneder jeg har været på aktiemarkedet, så falder kursen, når der kommer nye aktier. Er det fordi folk kan nå at få del i de nye billige aktier inden den 29/9 eller ???
  • Kan nogen fortælle mig, hvad der sker i Qliro Group? (-35%)

    1
    0 Votes
    1 Indlæg
    0 Visninger
    T
    Den er faldet med ca. 35% her til morgen. https://www.qlirogroup.com/en/media/press-releases/?id=6F87953ED4983E3C Udfra pressemeddelesen ser det ud som om at Qliro bliver delt op i 2 selskaber. "Ten (10) ordinary shares in Qliro Group entitle the holder to one (1) share in Qliro". Så, hvis jeg f.eks. har 100 aktier i Qliro Group, så vil jeg få 10 aktier i Qliro, er det korrekt forstået? Jeg har handlet det gennem Nordnet, men jeg kan ikke se nogen meddelelser om dette på Nordnet, jeg ville tro det skulle stå under Coorporate Actions, men jeg kan intet se. Foregår det mon automatisk...? Kan nogen fortælle mig om jeg har forstået nedenstående meddelselse, på engelsk, korrekt: 28 sept., altså i går. Qliro Group aktier kan handles frit, og hvis man købte ekstra i går, så vil man få yderligere aktier i Qliro. sept. altså i dag. Qliro aktier kan handles frit, men man får ikke yderligere aktier i Qliro. Er det derfor prisen falder på aktien i dag? sept. altså i morgen, man får tildelt aktier i Qliro (10 stk, hvis man havde 100 stk d. 28. sept). okt. Qliros aktier kan handles frit på Nasdaq Stockholm. "Timetable for distribution and listing 28 September 2020 Last day of trading in Qliro Group's ordinary share including the right to distribution of shares in Qliro 29 September 2020 Qliro Group's ordinary share is traded excluding the right to distribution of shares in Qliro 30 September 2020 Record date for receiving shares in Qliro 2 October 2020 Expected first day of trading in Qliro's share on Nasdaq Stockholm" Advisers Carnegie Investment Bank is financial adviser and Advokatfirman Cederquist is legal adviser in connection with the distribution of shares and listing of Qliro on Nasdaq Stockholm.
  • MDUNDO FORSÆTTER VÆKSTEN

    0
    0 Votes
    0 Indlæg
    0 Visninger
    Helge_LarsenPI-redaktørH
    Årsrapport for perioden 10. april - 30. juni 2020 29.9.2020 09:37:07 CEST ' Mdundo.com A/S ' Offentliggørelse af årsrapport Bestyrelsen i Mdundo.com A/S har godkendt selskabets første årsrapport gældende for perioden 10. april - 30. juni 2020, og fremlægger samtidig proforma tal for koncernen for perioden 1. juli 2019 - 30. juni 2020. Selskabsmeddelelse nr. 3-2020 Highlights: Bruger- og musikvækst: Ved afslutning af regnskabsåret den 30/6 2020 havde koncernen ca. 5 mio. unikke brugere per måned, hvilket var en stigning på 172% siden 1/7 2019. Mdundo havde ved afslutning af regnskabsåret 1,4 mio. internationale musiknumre samt +200.000 musiknumre (47% vækst fra 2019 til 2020) uploadet fra +80.000 afrikanske kunstnere til Mdundo.com. Stærke proformatal: Som forberedelse til børsnoteringen på Nasdaq First North Growth Market Denmark overtog Mdundo.com A/S (stiftet d. 10. april 2020) alle aktierne i Mdundo Ltd (selskabets operationelle datterselskab i Kenya) samt alle øvrige aktiver i Mdundo.com Ltd (koncernens tidligere moderselskab) pr. 29. april 2020. Dette betyder, at de finansielle resultater præsenteret i denne årsrapport kun indeholder datterselskabets finansielle resultater for perioden, hvor Mdundo Ltd var ejet af Mdundo.com A/S (29. april til 30. juni 2020), og dermed ikke et retvisende billede for koncernens samlede performance i perioden 1. juli 2019 til 30. juni 2020. Såfremt disse selskabers finansielle resultater inkluderes opnås en proforma omsætning for regnskabsåret på DKK 1,7 mio. og et EBITDA på DKK -2,1 mio. Omsætningen er ca. DKK 100.000 lavere end forventet, hvilket hovedsageligt skyldes en svækket Kenyansk Shilling, mens EBITDA var DKK 100.000 bedre end forventet. Indtægterne fra reklame er det seneste år øget med 234% efter implementering af en ny og succesrig kommerciel strategi. Begivenheder efter afslutning af regnskabsåret: Med udgangspunkt i en stærk brugerbase, content-offering og stigende indtægtsmuligheder anmodede Mdundo.com A/S d. 17. august 2020 om optagelse til handel på Nasdaq First North Growth Market Denmark og efter et succesfuldt udbud af nye aktier - som var overtegnet med 111% - blev Mdundo.com A/S optaget til handel på Nasdaq First North Growth Market Denmark med første handelsdag d. 4. september 2020 efter udstedelse 4 mio. nye aktier, hvilket gav Selskabet DKK 40 mio. i brutto-provenu. Outlook: Mdundo har tidligere meddelt, at antallet af månedlige aktive brugere forventes at stige med ca. 70-80% til 8,5-9,0 mio. i 2021 og stiger yderligere med ca. 100% til niveauet 18 mio. i 2022. Denne forventning gentages. Selskabets forventninger til omsætning og EBITDA for regnskabsåret 2020/21 fastholdes på tidligere udmeldte niveau. I forbindelse med anmodning om optagelse til handel på Nasdaq First North Growth Denmark og udarbejdelse af virksomhedsbeskrivelsen forventede Mdundo inden udgangen af 2020 at have implementeret det første partnerskab med et teleselskab. Denne forventning fastholdes. Jesper Vesten Drescher Bestyrelsesformand/Chairman of the board +4523229900 [email protected] Martin Nielsen CEO +254 708 911 840 [email protected] Selskabsmeddelse: https://via.ritzau.dk/ir-files/13560034/2391/2597/Download selskabsmeddelelse.pdf Årsrapport: https://via.ritzau.dk/ir-files/13560034/2391/2596/Annual Report 2020 - Mdundo.com AS.pdf
  • Teknisk analyse af Ørsted

    3
    0 Votes
    3 Indlæg
    0 Visninger
    Helge_LarsenPI-redaktørH
    Trend: Kort sigt - Op Lang sigt -Op Aktuel pris: 880 kroner Kort sigt: Aktien har på kort sigt bevæget sig i optrend siden marts 2020 og frem til i dag. Her har aktien bevæget sig med bund og støtteniveau i kurs 546kroner og med top og modstandsniveau i kurs 926 kroner, der ligeledes er ny all time high. I dag kan Ørsted aktien handles til kurs 880 kroner. Lang sigt: På lang sigt har Ørsted aktien været i optrend, og derfor er der god grund til at aktien vil fortsætte med at stige, og bryde den seneste top og modstandsniveau nedefra og op i kurs 926kroner.Denne kurs i 926kroner, er ligeledes aktiens all time hig og dermed et stærkt købssignal ved brud. Aktien har været i optrend siden november 2016 og frem til idag. Her lå den i bund og støtteniveau i kurs 229kroner, og steg opt il top og modstandsniveau i kurs 926 kroner.En stigning på lidt over 400 procent på 4 år. Opadgående retning: I opadgående retning har aktien første top og modstandsniveau i kurs 926 kroner. Bliver dette niveau brudt nedefra og op vil aktien frembringe et stærkt køb signal, da det er brud af ny all time high. Nedadgående retning: Her er der støtte til aktien nede ved bund og støtteniveau i 840 kroner. Dernæst i bund og støtteniveau i 727 og i kurs 546 kroner kroner. Dernæst i bund og støtteniveau i kurs 546 kroner.Brud herunder vil bekræfte at aktien har vendt til nedtrend. Afgørende bunde og støtteniveauer: 840 kroner, 727 kroner og 546 koner. Afgørende toppe og modstandsniveauer: 926kroner. De tekniske indikatorer bevæger sig i et sidelæns interval på dagsgrafen. Til gengæld ser de tekniske indikatorer på uge og månedsgrafen kursstærke ud, med højere toppe og bunde, samt stigende momentum.Dette kan bakke op om, at aktien vil forsøge at fortsætte sin optrend. Rida Abu-Shumar/Proinvestors Analyseteam [image: 87128_Chart___OErsted_d._27.09.20.png]
  • Teknisk analyse af Vestas

    1
    0 Votes
    1 Indlæg
    0 Visninger
    Helge_LarsenPI-redaktørH
    Trend: Kort sigt - Op Lang sigt-Op Aktuel pris: 956kroner Kort sigt: Aktien har på kort sigt har aktien været i optrend siden marts 2020 og frem til i dag. Her har aktien bevæget sig med bund og støtteniveau i kurs 473 kroner og med top og modstandsniveau i kurs 1004 kroner, der ligeledes er ny all time high. I dag kan aktien handles til kurs 956 kroner. Lang sigt: På lang sigt har aktien været i optrend. Der der god grund til formode, at aktien vil fortsætte med at stige og bryde den seneste top og modstandsniveau nedefra og op i kurs 1004 kroner. Kurs 1004 kroner er ligeledes aktiens all time high og dermed et stærkt købssignal. Aktien har været i optrend siden juli 2012 og frem til i dag. Her lå den i bund og støtteniveau i kurs 24kroner, og steg hop til top og modstandsniveau i kurs 1004 kroner. En stigning på hele 980 kroner på 8 år. Opadgående retning: I opadgående retning har aktien første top og modstandsniveau i kurs 1004 kroner. Bliver dette niveau brudt nedefra og op, vil aktien frembringe et stærkt købsignal, da det er brud af ny all time high. Ligeledes har aktien fuldendt en bundformation med toppe i kurs 698, der begyndte helt tilbage i september 2008 og blev fuldendt i december 2019. Formationsbund i kurs 24 kroner er fra juli 2012. Med denne bundformation vil det teknisk set et target i 1350 kroner, der også vil være ny all time high. Nedadgående retning: Her er der støtte til aktien nede ved bund og støtteniveau i kurs 905 kroner. Dernæst i bund og støtteniveau i kurs 799 kroner.Dernæst i bund og støtteniveau i kurs 734 kroner, og dernæst i bund og støtteniveau i kurs 473 kroner. Brud herunder vil bekræfte at aktien har vendt til nedtrend. Afgørende bunde og støtteniveauer: 905 kroner, 799 kroner, 734 kroner og 473 kroner. Afgørende toppe og modstandsniveauer: 1004 kroner. De tekniske indikatorer bevæger sig i et sidelæns interval på dagsgrafen. Til gengæld ser de tekniske indikatorer på uge og månedsgrafen kursstærke ud, med højere toppe og bunde, samt stigende momentum. Dette kan bakke op om, at aktien vil forsøge at fortsætte sin optrend. Rida Abu-Shumar/ProInvestors Analyseteam [image: 87116_Chart___Vestas_d._27.09.20_.png]